Literature DB >> 23786278

Role of CCL18 in asthma and lung immunity.

A Tsicopoulos1, Y Chang, S Ait Yahia, P de Nadai, C Chenivesse.   

Abstract

Allergic asthma is a prototypic Th2 mediated disease, where chemokines orchestrate the inflammatory cell recruitment. Most chemokines have a pro-inflammatory role. In this review, we focus on the potential role, in asthma and lung immunity, of CCL18 a chemokine both constitutively expressed at high levels in the lung and induced in inflammatory conditions. This chemokine is mainly produced by antigen presenting cells, and induced by Th2 type cytokines. The available data suggest that this chemokine may exhibit dual functions, with both pro- and anti-inflammatory properties, the latter through its ability to generate adaptive regulatory T cells in healthy subjects, with a loss of function in allergic patients. However, the functional implications are at the moment hampered by the lack of data on the nature of its putative receptor, and the absence of murine orthologue.
© 2012 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23786278     DOI: 10.1111/cea.12065

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

1.  Blood Levels of Indicators of Lower Respiratory Tract Damage in Chronic Bronchitis in Patients with Abdominal Obesity.

Authors:  Elena V Kashtanova; Yana V Polonskaya; Evgeniia V Striukova; Liliia V Shcherbakova; Evgenii A Kurtukov; Viktoriya S Shramko; Ekaterina M Stakhneva; Yulia I Ragino
Journal:  Diagnostics (Basel)       Date:  2022-01-25

2.  CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN.

Authors:  Silke R Brix; Gesa Stege; Erik Disteldorf; Elion Hoxha; Christian Krebs; Sonja Krohn; Benjamin Otto; Kristin Klätschke; Elisabeth Herden; Felix Heymann; Sergio A Lira; Frank Tacke; Gunter Wolf; Martin Busch; Wolfram J Jabs; Fedai Özcan; Frieder Keller; Joachim Beige; Karl Wagner; Udo Helmchen; Mercedes Noriega; Thorsten Wiech; Ulf Panzer; Rolf A K Stahl
Journal:  J Am Soc Nephrol       Date:  2015-03-11       Impact factor: 10.121

3.  PARC/CCL18 is Associated with Inflammation, Emphysema Severity and Application of Inhaled Corticosteroids in Hospitalized COPD Patients.

Authors:  Hongxia Duan; Long Liang; Xinyang Liu; Shuanshuan Xie; Changhui Wang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-05-10

4.  Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma.

Authors:  Hongfei Wang; Xueyi Liang; Mianxiang Li; Xiaoan Tao; Shanshan Tai; Zhaona Fan; Zhi Wang; Bin Cheng; Juan Xia
Journal:  Cancer Sci       Date:  2017-07-18       Impact factor: 6.716

Review 5.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

6.  Natural Killer Cells from Allergic Donors Are Defective in Their Response to CCL18 Chemokine.

Authors:  Latiffa Amniai; Coline Ple; Mathieu Barrier; Patricia de Nadai; Philippe Marquillies; Han Vorng; Cécile Chenivesse; Anne Tsicopoulos; Catherine Duez
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

7.  Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia.

Authors:  Weiwei Qi; Yu Zhang; Wenhao Yang; Chunyan Liu; Huaquan Wang; Rong Fu; Zonghong Shao
Journal:  Dis Markers       Date:  2022-05-06       Impact factor: 3.434

Review 8.  Mast cell tissue heterogeneity and specificity of immune cell recruitment.

Authors:  Peter W West; Silvia Bulfone-Paus
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.